,
Channing J. Paller, M.D.

Assistant Professor of Oncology and Urology
Sidney Kimmel Comprehensive Cancer Center
Faculty Director, Specimen Accessioning Core
Sibley Memorial Hospital, Washington, DC.

Channing J. Paller, M.D, is Assistant Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Paller earned her M.D. at Harvard Medical School and completed her medical residency at the Johns Hopkins Hospital, where she was a member of the Osler Housestaff Program, and her Fellowship in Medical Oncology at the Johns Hopkins Kimmel Cancer Center.

As an investigator, Dr. Paller is focused on translational research and clinical trials of developmental therapeutics in prostate and other solid tumors.  Her research focus is on the evaluation of new therapies, such as spindle checkpoint inhibitors and histone deacetylases inhibitors.   Dr. Paller actively participates in the Johns Hopkins Kimmel Cancer Center Phase I program, with a concentration on the rigorous evaluation of natural products. She is collaborating with Genitourinary Division Director, Dr. Michael Carducci on novel clinical trials of natural products in men with rising PSA after localized therapy for prostate cancer, and was recently awarded a grant to complete an investigator-initiated  Phase II clinical trial of muscadine grape skin powder in that patient population.

Dr. Paller has earned honors throughout her young career as a scientist. She was selected for both a 2011-12 Young Investigator Award by the American Society of Clinical Oncology (ASCO) and for the 2011-12 ECOG Paul Carbone Award.  During her undergraduate education, she interned at the National Institutes of Health where she performed live cell microscopy. Before her work at Johns Hopkins, Dr. Paller also spent time at the Weizmann Institute in Israel’s Department of Biological Regulation, Massachusetts General Hospital’s Endocrine Unit, and McCord Hospital in South Africa, where she participated in the Harvard AIDS project.

While completing her Fellowship in oncology at Johns Hopkins Kimmel Cancer Center, Dr. Paller spent time at both the U.S. Food and Drug Administration and the National Cancer Institute’s Cancer Therapy Evaluation Program (CTEP).  Her collaboration with CTEP has continued since returning to Johns Hopkins.

 



Education

  • Training

    • Harvard Medical School (Boston MA) (2005)

    Residencies

    • The Johns Hopkins Hospital/ Medicine (Baltimore MD) (2008)

    Fellowships

    • The Johns Hopkins Hospital/ Hematology/Oncology (Baltimore MD) (2012)


Licensure & Certifications

  • Medical Oncology, American Board of Internal Medicine (2010)
  • Internal Medicine, American Board of Internal Medicine (2008)


Publications

Free Access to abstracts at PubMed 

Publications

  1. Somjen, D., Paller, C., Gayer, B., Kohen, F., Knoll, E. and Stern, N. High glucose blocks estradiol's effects on human vascular cell growth: differential interaction with estradiol and raloxifene. Journal of Steroid Biochemistry and Molecular Biology. 2004; 88:101-110. PMCID: 3638755. 

  2. Paller CJ, Shiels MS, Rohrmann S, Basaria S, Rifai N, Nelson W, Platz EA, Dobs A. Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men Clinical endocrinology. 2009;(1):26-34. PMCID: 3494466. 

  3. Paller C., Campbell, C., Edwards, R., Dobs A. Sex-based differences in pain perception and treatment. Pain Medicine. 2009 Mar;10(2):289-99. PMCID: 2745644. 

  4. Paller CJ, Rudin CM. Youth has no age: cancer treatment for older Americans. Oncology (Williston Park, N.Y.). 2010 Nov 15;24(12):1114, 1118, 1120. PMCID: 3482117. 

  5. Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug design, development and therapy. 2011 Mar 10;5:117-24. PMCID: 3063116. 

  6. Paller, C., Ye, X, Wozniak, P., Gillespie, B., Sieber, P., Greengold, R., Stockton, B., Hertzman, B., Efros, M., Roper, R., Liker, H., Carducci, M.. A phase II study of pomegranate extract for men with rising prostate specific antigen following primary therapy. Prostate Cancer and Prostatic Diseases. 2013 March; PMCID: 3549301.

  7. Paller CJ, Antonarakis ES. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. Human vaccines and immunotherapeutics. 2012;8(4):509-19. 

  8. Paller CJ, Smith TJ. Finasteride and prostate cancer: a commentary. The Oncologist. 2012;17(7):888-90. PMCID: 3399642.

  9. Paller CJ, Shiels MS, Rohrmann S, Menke A, Rifai N, Nelson WG, Platz EA, Dobs AS. Association between Sex Steroid Hormones and Hematocrit in a Nationally-Representative Sample of Men. Journal of Andrology. 2012 Nov-Dec; 33(6): 1332-41. PMCID: 3774012.

  10. Paller CJ, Carducci MA, Philips GK. Management of bone metastases in refractory prostate cancer - role of denosumab. Clinical interventions in aging. 2012;7:363-72. PMCID: 3459574. 

  11. Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clinical advances in hematology and oncology: H&O. 2013 Jan;11(1):14-23. PMCID: 3624708.

  12. Paller CJ., Antonarakis EA., Eisenberger M., Carducci, Management of patients with biochemical recurrence after local therapy for prostate cancer in Hematology/Oncology.  Clinical Advances in Hematology and Oncology. 2013 Jan;11(1):14-23.  PMCID:  3624708.

  13. Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA.  A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013 Marc;16(1):50-5. PMCID: 3549301.


Memberships

2002-2004

Member, American College of Physicians (ACP)

2002-2004

Student Representative, Massachusetts Medical Society

2009-Present

Full Member, American Society of Clinical Oncology (ASCO)

2010-Present

Associate Member, American Association for Cancer Research (AACR)

2012-Present

Clinical Trial Design Task Force, Investigational Drug Steering Committee (IDSC)



Awards & Honors

2010

AACR Vail Methods in Clinical Cancer Research Workshop, Vail, CO (invited participant)

2011

Merit Award to attend 2011 ASCO Annual Conference

2011-2012

Paul Carbone ECOG Fellowship

2011-2012

ASCO Conquer Cancer Foundation Young Investigator Award

2012

Merit Award to attend 2012 ASCO Annual Conference

2012

19th Annual Scientific Retreat of the Prostate Cancer Foundation (invited participant)

2013

Multi-Institutional Prostate Cancer Program Retreat. Ft. Lauderdale, FL. (Invited participant)

2013

Ninth International Workshop on Anticancer Agents, Northumberland, UK (Invited participant)